Evidence map›Paper›PMID 42215983›Full record

ArticleJournal of ovarian research2026

Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study.

Hanna Roos Alexander, Shamima Afrin Ruma, Shruti Jain, Eva Lundin, Per Liv, Pernilla Israelsson, Kim Pettersson, Annika Idahl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanna Roos AlexanderDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Universitetstorget 4, Umeå, 901 87, Sweden. hanna.roos@umu.se.
Shamima Afrin RumaDepartment of Life Technologies and FICAN West Cancer Centre, University of Turku, Turku, Finland.
Shruti JainDepartment of Life Technologies and FICAN West Cancer Centre, University of Turku, Turku, Finland.
Eva LundinDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Per LivDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Pernilla IsraelssonDepartment of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Kim PetterssonDepartment of Life Technologies and FICAN West Cancer Centre, University of Turku, Turku, Finland.
Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Universitetstorget 4, Umeå, 901 87, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNanoparticle immunoassays for CA125 and CA15-3 glycovariants are promising tools for epithelial ovarian cancer (EOC) and borderline ovarian tumor (BOT) early detection.

methodThis retrospective population-based study utilized prospective (< 3 years) plasma samples from 110 cases and 440 controls. Sialyl-Thomsen-nouveau (STn) antibody and macrophage galactose-type lectin (MGL) to detect cancer antigen 125 (CA125) and 15 - 3 (CA15-3) glycoforms were evaluated, using CA125, CA15-3, and HE4 enzyme immunoassay (EIA) references. The area under the receiver operating characteristic curve (AUC), partial AUC (pAUC) at specificities 0.9-1.0, and sensitivity (SN) at 0.98 specificity (SP) for detecting EOC/BOT were calculated.

resultsThe single marker with the highest point estimate for pAUC and SN at 98% SP was CA125

conclusionThis case-control study, which used plasma samples collected up to three years before diagnosis of EOC or BOT, did not provide evidence of a higher discriminatory capacity of the glycovariant biomarkers compared with the clinically established biomarker CA125

Indexed as

Biomarkers, TumorCA-125 AntigenMembrane ProteinsMucin-1Ovarian NeoplasmsAdultAgedCase-Control StudiesFemaleHumansMiddle AgedRetrospective StudiesROC CurveBiomarkers, TumorCA-125 AntigenMembrane ProteinsMUC16 protein, humanMucin-1BiomarkersCA125Early detectionEpithelial ovarian cancerGlycovariantProspective samples

Identifiers

PMID42215983
PMCPMC13220484

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.